Gene therapy trial hopes to fix heart muscle in rare genetic disease

NCT ID NCT06109181

First seen Nov 12, 2025 · Last updated May 12, 2026 · Updated 21 times

Summary

This early-stage trial tests a gene therapy called LX2020 in 10 adults with a rare, inherited heart condition (PKP2-ACM) that can cause dangerous heart rhythms and heart failure. The therapy is given once through a vein and aims to deliver a working copy of the PKP2 gene to heart cells. The main goal is to check safety, but researchers will also look for signs that the treatment improves heart function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Stanford University

    Stanford, California, 94305, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Rochester

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.